SESSION LECTURE

No. 58

New Drug Discovery

Room: 308

Co-Chairs: Guanhua Du  **S J Enna** 

Day 3 October 29th (Monday) 8:30 – 12:00		
Time	**Speaker**	**Title**
8:30-9:00	**Guanhua Du** *Institute of Materia Medica, CAMS, China*	The Strategy of Active Natural Product and Traditional Chinese Medicine based Drug discovery
9:00-9:30	**S J Enna** *Kansas University Medical Center, USA*	Central nervous system drug discovery
9:30-10:00	**Daniel Hoyer** *The University of Melbourne, Australia*	Orexin receptor antagonists for insomnia treatment: preclinical, clinical and regulatory aspects
10:00-10:15	**Tea Break**	
10:15-10:45	**Zhongping Feng** *University of Toronto, Canada*	GSK-3β inhibitor reduced neonatal hypoxic-ischemic brain injury in mice
10:45-11:15	**Hongshuo Sun** *University of Toronto, Canada*	Effects of Marine Compound on Neuroprotection and Potential Drug Development
11:15-11:45	**Jia Li** *Shanghai Institute of Materia Medica, CAS, China*	Novel Strategy for Hyperglycemia Therapy Targeting to Mitochondria
11:45-12:15	**Wenxia Zhou** *Beijing Institute of Pharmacology and toxicology, China*	Modulating the Balance of Synaptic and Extrasynaptic NMDA Receptors as a strategy for Alzheimer's diseasedrug discovery

Guanhua Du

dugh@imm.ac.cn

Dr. Du is mainly engaged in drug discovery and development, screening methods and strategy, and drug effect and mechanism research in cerebrovascular and neurodegenerative disease. He originated the national high-throughput drug screening system in China, and provided drug screening services for over 300 million numbers of samples for domestic pharmaceutical institutions or enterprises.

Daniel Hoyer

d.hoyer@unimelb.edu.au

Prof. Hoyer's team works on sleep/wake regulation, attention and decision making in health and disease, especially Alzheimer's disease. He had various leading positions in Cardiovascular and Neuropsychiatry research during > 30 years with Sandoz / Novartis Pharma in Switzerland and the US. Hoyer has also a strong interest in translational aspects of 5-HT and neuropeptides and their receptors, as well as in receptor nomenclature.

Hong-Shuo Sun

hss.sun@utoronto.ca

Associate Professor (tenured), PhD Supervisor, Departments of Surgery, Physiology and Pharmacology, Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Canada

Jia Li

jli@simm.ac.cn

Professor Li research on identification of novel drug candidates for type 2 diabetes, fibrosis in different organs and Hematologic malignancies. He serves as Deputy Director in-General of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the director of State Key Laboratory for Drug Research.

S J Enna

senna@kumc.edu

Dr. Enna's research focused on defining the pharmacological and biochemical properties of neurotransmitter receptors, in particular those for GABA. He is Editor-in-Chief of Biochemical Pharmacology, Pharmacology & Therapeutics, Current Protocols in Pharmacology, and Advances in Pharmacology and is Past-President of the American Society of Pharmacology and Experimental Therapeutics (ASPET) and of the International Union of Basic and Clinical Pharmacology (IUPHAR)

Zhong-Ping Feng

zp.feng@utoronto.ca

Professor (tenured), PhD Supervisor and Graduate Coordinator, Department of Physiology, Faculty of Medicine; Director of International Development at IMS; Director of Collaborative Specialization Program In Neuroscience, University of Toronto, Canada.

Wenxia Zhou

zhouwx@bmi.ac.cn

Dr. Zhou's research interests include the study of function of neuroendocrine immunomodulation (NIM) network and the pharmacological studies of immunomodulators, endocrinomoduators, anti-ageing (especially anti-Alzheimer's disease) and cognition-enhancing drugs. She is also Deputy Secretary-General and the Executive Member of the Council of Chinese Pharmacological Society (CNPHARS), and Chair of the Committee of Network Pharmacology of CNPHARS.